Drugs used to treat rheumatic and musculospastic disease. In, Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver.
Philadelphia: Lippincott,pp. Expert review of hepatotoxicity published inlong before the availability of sarilumab and other monoclonal antibodies. Immunosuppressants, tolerogens, and immunostimulants. New York: McGraw-Hill,pp.
Textbook of pharmacology and therapeutics.
Carroll MB. The impact of biologic response modifiers on hepatitis B virus infection. Expert Opin Biol Ther.
Bannwarth B, Richez C. Clinical safety of tocilizumab in rheumatoid arthritis. Expert Opin Drug Saf. Case of severe liver damage after the induction of tocilizumab therapy for rheumatoid vasculitis. Hepatol Res. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis ADACTA : a randomised, double-blind, controlled phase 4 trial.
Severe hepatitis associated with tocilizumab in a patient with rheumatoid arthritis. Rheumatology Oxford. Tocilizumab-induced acute liver injury in adult onset Still's disease.
Case Reports Hepatol. Ann Rheum Dis. Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a phase III study.
Arthritis Rheumatol. Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis MONARCH : a randomised, double-blind, parallel-group phase III trial.
Sarilumab and nonbiologic disease-modifying antirheumatic drugs in patients 2ith active rheumatoid arthritis and inadequate response or intolerance to tumor necrosis factor inhibitors.
Scott LJ. Sarilumab: First global approval. FDA safety review of elevations in liver associated enzymes during sarilumab therapy.